Categories

Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2023 – Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market

US$ 4995

Non-Small Cell Lung Cancer (NSCLC) is the most common cancer and the leading cause of cancer-related mortality globally. There were more than 1.8 million newly diagnosed lung cancer cases in 2012, accounting for 13% of the total number of cancer cases.

04-04 2017   Pages: 161

Frontier Pharma: Head and Neck Cancer – Immunotherapies and Signal Transduction Inhibitors Dominate First-in-Class Innovation

US$ 6995

Head and neck squamous cell carcinoma is the sixth most common cancer, and its incidence is rising. The term head and neck cancer (HNC) comprises a number of malignancies that usually begin in the squamous cells that line the moist, mucosal surfaces inside the head and neck.

04-04 2017   Pages: 78

Global Respiratory Complications Therapeutics Market to 2022 – Innovative Pneumonia and Pulmonary Arterial Hypertension Therapies Dominate Varied Disease Market

US$ 4995

The respiratory therapy area consists of indications that affect the respiratory system in various ways, including the scarring of lung tissue and excessive production of mucus in the airways, thereby decreasing lung function.

04-04 2017   Pages: 197

Seasonal Influenza Therapeutics in Asia-Pacific Markets to 2022 – Growth Driven by Rising Elderly Population, Growing Awareness and Launch of Quadrivalent Therapies

US$ 4995

Influenza, often referred to as the flu, is an acute infection caused by one of the three closely related viruses, designated as influenza Type A, B, and C. The infection’s rapid onset and potential for high morbidity and mortality, particularly in high-risk patient populations such as the elderly and young children, make prompt and effective treatment with antiviral medication very difficult.

02-03 2017   Pages: 108

Global Cardiovascular Disease Market to 2022 – Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth

US$ 4995

“Global Cardiovascular Disease Market to 2022 – Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth

11-14 2016   Pages: 192

Frontier Pharma: Ophthalmology Therapeutics – Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the Way

US$ 6995

“Frontier Pharma: Ophthalmology Therapeutics – Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the Way

11-14 2016   Pages: 70

Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 – Growth Driven by Increasing Prevalence and Launch of Targeted Therapies

US$ 4995

“Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 – Growth Driven by Increasing Prevalence and Launch of Targeted Therapies

11-09 2016   Pages: 112

Frontier Pharma: Glioblastoma Multiforme – Cancer Immunotherapies Dominate First-in-Class Product Innovation

US$ 6995

“Frontier Pharma: Glioblastoma Multiforme – Cancer Immunotherapies Dominate First-in-Class Product Innovation

11-09 2016   Pages: 73

Frontier Pharma: Glioblastoma Multiforme – Cancer Immunotherapies Dominate First-in-Class Product Innovation

US$ 6995

Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is the most common and aggressive human brain tumor, accounting for 15.4% of all primary brain tumors and 60-75% of all astrocytomas.

10-17 2016   Pages: 73

Alzheimer’s Therapeutics in Asia-Pacific Markets to 2021 – Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Disease Modifying Therapies

US$ 4995

Alzheimer’s Disease (AD) is an irreversible, progressive neurodegenerative disease, characterized by cognitive impairment, memory loss and functional decline. Symptoms typically begin to first occur in patients in their mid-sixties, appearing in varying stages.

04-15 2016   Pages: 151
Contact With Us
Join templatemonster at google+
Customized Research
Request Sample